TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of renal cell cancer.

Think of last pt who died of mCRC: No. lines of Tx received? Did that pt receive regorafenib?

Think back to the last patient in your practice who died of mCRC: How many lines of therapy did that patient receive?

Did that patient receive regorafenib at some point during his or her course of metastatic disease?

Think of last pt who died of mCRC: No. lines of Tx received? Did that pt receive regorafenib?

Think back to the last patient in your practice who died of mCRC: How many lines of therapy did that patient receive?

Did that patient receive regorafenib at some point during his or her course of metastatic disease?

How to manage regorafenib for a pt on 160-mg dose w/ HFS and painful erythema, swelling (Gr 2)>

How to manage regorafenib for a pt on 160-mg dose w/ HFS and some erythema, skin peeling but no pain (Gr 1)?

A 67-year-old patient with extensive prior treatment for metastatic colorectal cancer (mCRC) is started on regorafenib 160 mg orally daily for 21 days every 28 days. About a week later, the patient develops Grade 2 hand-foot syndrome. What would you do at this time?